246C10 |
An ionizable cationic lipid (pKa = 6.75); has been used in combination wit… |
25 mg |
37907-25 |
More Info
|
246C10 |
An ionizable cationic lipid (pKa = 6.75); has been used in combination wit… |
5 mg |
37907-5 |
More Info
|
680C91 |
A TDO inhibitor (IC50s = 1.46 and 0.28 µM for the mouse and human en… |
10 mg |
34823-10 |
More Info
|
680C91 |
A TDO inhibitor (IC50s = 1.46 and 0.28 µM for the mouse and human en… |
25 mg |
34823-25 |
More Info
|
680C91 |
A TDO inhibitor (IC50s = 1.46 and 0.28 µM for the mouse and human en… |
5 mg |
34823-5 |
More Info
|
680C91 |
A TDO inhibitor (IC50s = 1.46 and 0.28 µM for the mouse and human en… |
50 mg |
34823-50 |
More Info
|
C-02 |
A PROTAC that drives hexokinase 2 degradation; induces degradation of hexo… |
1 mg |
39384-1 |
More Info
|
C-02 |
A PROTAC that drives hexokinase 2 degradation; induces degradation of hexo… |
5 mg |
39384-5 |
More Info
|
C-02 |
A PROTAC that drives hexokinase 2 degradation; induces degradation of hexo… |
500 µg |
39384-500 |
More Info
|
C12-113 |
An ionizable cationic lipidoid; has been used in combination with other li… |
10 mg |
39335-10 |
More Info
|
C12-113 |
An ionizable cationic lipidoid; has been used in combination with other li… |
25 mg |
39335-25 |
More Info
|
C12-113 |
An ionizable cationic lipidoid; has been used in combination with other li… |
5 mg |
39335-5 |
More Info
|
C12-200 |
A branched-chain ionizable cationic lipidoid; has been used in combination… |
10 mg |
36699-10 |
More Info
|
C12-200 |
A branched-chain ionizable cationic lipidoid; has been used in combination… |
100 mg |
36699-100 |
More Info
|
C12-200 |
A branched-chain ionizable cationic lipidoid; has been used in combination… |
25 mg |
36699-25 |
More Info
|
C12-200 |
A branched-chain ionizable cationic lipidoid; has been used in combination… |
50 mg |
36699-50 |
More Info
|
C14-4 |
An ionizable cationic lipid; has been used in the generation of lipid nano… |
1 mg |
38942-1 |
More Info
|
C14-4 |
An ionizable cationic lipid; has been used in the generation of lipid nano… |
10 mg |
38942-10 |
More Info
|
C14-4 |
An ionizable cationic lipid; has been used in the generation of lipid nano… |
5 mg |
38942-5 |
More Info
|
C-170 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
10 mg |
30157-10 |
More Info
|
C-170 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
100 mg |
30157-100 |
More Info
|
C-170 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
25 mg |
30157-25 |
More Info
|
C-170 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
50 mg |
30157-50 |
More Info
|
C-171 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
10 mg |
30159-10 |
More Info
|
C-171 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
100 mg |
30159-100 |
More Info
|
C-171 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
25 mg |
30159-25 |
More Info
|
C-171 |
A STING inhibitor; binds to STING, inhibits its palmitoylation, and preven… |
50 mg |
30159-50 |
More Info
|
C-176 |
A STING inhibitor; reduces STING-, but not RIG-I or TBK1-, mediated IFN-&b… |
10 mg |
25859-10 |
More Info
|
C-176 |
A STING inhibitor; reduces STING-, but not RIG-I or TBK1-, mediated IFN-&b… |
100 mg |
25859-100 |
More Info
|
C-176 |
A STING inhibitor; reduces STING-, but not RIG-I or TBK1-, mediated IFN-&b… |
25 mg |
25859-25 |
More Info
|
C-176 |
A STING inhibitor; reduces STING-, but not RIG-I or TBK1-, mediated IFN-&b… |
50 mg |
25859-50 |
More Info
|
C-178 |
A STING inhibitor; binds to Cys91 on STING to block its and prevents recru… |
10 mg |
25860-10 |
More Info
|
C-178 |
A STING inhibitor; binds to Cys91 on STING to block its and prevents recru… |
25 mg |
25860-25 |
More Info
|
C-178 |
A STING inhibitor; binds to Cys91 on STING to block its and prevents recru… |
5 mg |
25860-5 |
More Info
|
C-178 |
A STING inhibitor; binds to Cys91 on STING to block its and prevents recru… |
50 mg |
25860-50 |
More Info
|
C18 |
A covalent GPX4 inhibitor (IC50 = 120 nM); inhibits the growth of MDA-MB-4… |
1 mg |
39432-1 |
More Info
|
C18 |
A covalent GPX4 inhibitor (IC50 = 120 nM); inhibits the growth of MDA-MB-4… |
10 mg |
39432-10 |
More Info
|
C18 |
A covalent GPX4 inhibitor (IC50 = 120 nM); inhibits the growth of MDA-MB-4… |
25 mg |
39432-25 |
More Info
|
C18 |
A covalent GPX4 inhibitor (IC50 = 120 nM); inhibits the growth of MDA-MB-4… |
5 mg |
39432-5 |
More Info
|
C188-9 |
A STAT3 inhibitor; binds to the STAT3 SH2 domain (Ki = 136 nM) and inhibit… |
10 mg |
30928-10 |
More Info
|
C188-9 |
A STAT3 inhibitor; binds to the STAT3 SH2 domain (Ki = 136 nM) and inhibit… |
25 mg |
30928-25 |
More Info
|
C188-9 |
A STAT3 inhibitor; binds to the STAT3 SH2 domain (Ki = 136 nM) and inhibit… |
5 mg |
30928-5 |
More Info
|
C188-9 |
A STAT3 inhibitor; binds to the STAT3 SH2 domain (Ki = 136 nM) and inhibit… |
50 mg |
30928-50 |
More Info
|
C25-140 |
An inhibitor of the TRAF6-Ubc13 protein-protein interaction (IC50 = 2.6 &m… |
1 mg |
39669-1 |
More Info
|
C25-140 |
An inhibitor of the TRAF6-Ubc13 protein-protein interaction (IC50 = 2.6 &m… |
10 mg |
39669-10 |
More Info
|
C25-140 |
An inhibitor of the TRAF6-Ubc13 protein-protein interaction (IC50 = 2.6 &m… |
25 mg |
39669-25 |
More Info
|
C25-140 |
An inhibitor of the TRAF6-Ubc13 protein-protein interaction (IC50 = 2.6 &m… |
5 mg |
39669-5 |
More Info
|
C2-8 |
An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 µM for recomb… |
1 mg |
21177-1 |
More Info
|
C2-8 |
An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 µM for recomb… |
10 mg |
21177-10 |
More Info
|
C2-8 |
An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 µM for recomb… |
25 mg |
21177-25 |
More Info
|
C2-8 |
An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 µM for recomb… |
5 mg |
21177-5 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
1 mg |
27029-1 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
10 mg |
27029-10 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
25 mg |
27029-25 |
More Info
|
C29 |
An inhibitor of TLR2 signaling; inhibits synthetic and bacterial TLR2 agon… |
5 mg |
27029-5 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
1 mg |
33166-1 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
10 mg |
33166-10 |
More Info
|
C3 |
An inhibitor of MAO-B (IC50 = 0.021 µM); selective for MAO-B over MA… |
5 mg |
33166-5 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
10 mg |
21771-10 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
25 mg |
21771-25 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
5 mg |
21771-5 |
More Info
|
C527 |
An inhibitor of the USP1 / UAF complex; inhibits USP1 / UAF deubiquitinase… |
50 mg |
21771-50 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
1 mg |
37354-1 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
10 mg |
37354-10 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
5 mg |
37354-5 |
More Info
|
C53 |
A STING agonist; activates human wild-type STING (EC50 = 185 nM), as well… |
50 mg |
37354-50 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
1 mg |
10549-1 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
10 mg |
10549-10 |
More Info
|
C646 |
An inhibitor of the HAT p300 (IC50 = 1.6 µM); competitively binds p3… |
5 mg |
10549-5 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
1 g |
21601-1 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
100 mg |
21601-100 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
250 mg |
21601-250 |
More Info
|
C-7280948 |
A PRMT1 inhibitor (IC50 = 12.8 µM, in vitro) |
500 mg |
21601-500 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
1 mg |
33563-1 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
10 mg |
33563-10 |
More Info
|
C82 |
An Mtb CdnP inhibitor (IC50 = 17.5 µM); selective for Mtb CdnP over… |
5 mg |
33563-5 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
10 mg |
36578-10 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
25 mg |
36578-25 |
More Info
|
C-87 |
An inhibitor of TNF-α; binds to TNF-α; inhibits TNF-α-in… |
5 mg |
36578-5 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
10 mg |
40863-10 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
25 mg |
40863-25 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
5 mg |
40863-5 |
More Info
|
C10-200 |
An ionizable cationic lipid; has been used in the generation of LNPs for t… |
50 mg |
40863-50 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
1 mg |
31064-1 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
10 mg |
31064-10 |
More Info
|
C3001a |
An activator of K2P2.1 / TREK1 and K2P10.1 / TREK2; increases current ampl… |
5 mg |
31064-5 |
More Info
|
CA-074 |
A selective cathepsin B inhibitor (Kis = 0.0087, 75, and 233 µM for… |
1 mg |
24679-1 |
More Info
|
CA-074 |
A selective cathepsin B inhibitor (Kis = 0.0087, 75, and 233 µM for… |
500 µg |
24679-500 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
1 mg |
27598-1 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
10 mg |
27598-10 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
25 mg |
27598-25 |
More Info
|
CA-4948 |
An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-typ… |
5 mg |
27598-5 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
1 mg |
37300-1 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
10 mg |
37300-10 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
25 mg |
37300-25 |
More Info
|
CA77.1 |
An inducer of chaperone-mediated autophagy; induces the formation of autop… |
5 mg |
37300-5 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
1 mg |
40256-1 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
10 mg |
40256-10 |
More Info
|
C14-A1 |
An ionizable cationic lipid; has been used in the generation of LNPs; LNPs… |
5 mg |
40256-5 |
More Info
|
Cabazitaxel |
A semisynthetic taxane; stabilizes microtubule assembly by reducing lag ti… |
10 mg |
22262-10 |
More Info
|